Andrew A. Lane, MD, PhD discuss results from a phase 2 Study
Dana-Farber
December 18, 2025
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendtritic cell neoplasm (BPDCN)